Latest From University Hospitals
BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.
The Cleveland-based biopharma accelerator company signs a $40 million agreement with Torrey Pines Investment to provide early-stage funding and development for innovations emerging from academic research. Previously, BioMotiv raised $46 million from investors to fund its model of accelerating breakthrough discoveries into mid-stage development.
Backed by a Cleveland family foundation and powerful hospital group, the for-profit BioMotiv wants to do biopharma asset financing on its own terms.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.